论文信息 - Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread? - 字舞流文

Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?

S. Novello | S. Cappia | P. Bironzo | F. Tabbò | L. Righi | G. Cortese | A. D’Aveni | D. Pignataro | S. Carnio | Daniele Tota

[1] D. Montani,et al. Lorlatinib - Induced pulmonary arterial hypertension. , 2018, Lung cancer.

[2] Corinne Miller,et al. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer , 2018, Oncotarget.

[3] S. Novello,et al. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. , 2017, Critical reviews in oncology/hematology.

[4] Serafino Pantano,et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[5] T. Welte,et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. , 2011, The American journal of pathology.